ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2003
Managing taxane toxicities.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Pooled it
- Prognostic value of platelet to lymphocyte ratio in patients with castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis.International journal of nanomedicine · 2020Pooled it
- Dermatological adverse events with taxane chemotherapy.European journal of dermatology : EJD · 2016Pooled it
- Pooled it
- 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.British journal of clinical pharmacology · 2015Trial
- Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.Journal of neuro-oncology · 2008Trial
- Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.Cancer chemotherapy and pharmacology · 2026Article
- Disruption of microtubules with low intensity ultrasound rescues hair follicle damage by paclitaxel in mouse models.Nature communications · 2026Article
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- Docetaxel-Induced Serositis Mimicking Malignant Pleural Effusion.Clinical case reports · 2026Article
- Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.Drug design, development and therapy · 2026Review
- Tailoring the Release of Paclitaxel from Electrospun Nonwovens.International journal of molecular sciences · 2025Article
- Three New Physalins fromMolecules (Basel, Switzerland) · 2025Article
- Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025Article
- Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Antinociceptive Effect ofLife (Basel, Switzerland) · 2023Article
- Milk/colostrum exosomes: A nanoplatform advancing delivery of cancer therapeutics.Cancer letters · 2023Review
- Article
- Nanoparticle-based radiosensitization strategies for improving radiation therapy.Frontiers in pharmacology · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The two commercially available taxanes (paclitaxel and docetaxel) are widely employed in standard oncologic practice. Toxicity of the agents includes bone marrow suppression (principally neutropenia), complete alopecia, and hypersensitivity reactions. While both drugs can cause neurotoxicity and myalgias/arthralgias, this is a greater clinical concern with paclitaxel. Docetaxel can be associated with the development of significant fluid retention (e.g., edema, ascites, pleural effusions), the incidence and severity of which appear to be limited by prophylactic treatment with corticosteroids both before and after each treatment. If patients are monitored closely (e.g., for hypersensitivity reactions, bone marrow suppression) the taxanes have a favorable side effect profile, and it is currently uncommon for treatment to be discontinued because of the development of excessive toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.